More infants in formula-fed versus breastfed group developed iron deficiency, despite having higher mean total daily iron intake.
Odronextamab has demonstrated safety and efficacy in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.
Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.
Worldwide, bortezomib-based triplets are the most common frontline treatment for multiple myeloma, but regimens used in later lines vary.
PTCy plus tacrolimus and MMF should be standard GVHD prophylaxis in adults who receive a well-matched PBSCT after RIC, according to researchers.
Researchers sought to assess the risk of progression to ITP or hematologic neoplasia in adults with persistent, isolated mild thrombocytopenia.
Researchers sought to determine whether there was a link between socioenvironmental experiences and a particular immunoregulatory pattern in recipients of HCT.
Researchers sought to determine whether MRI could show evidence of brain infarction in patients with iTTP.
Researchers sought to determine whether low-dose lenalidomide would prolong time to transfusion dependence among patients with low-risk MDS.
Zanubrutinib prolongs progression-free survival, when compared with ibrutinib, in patients with relapsed/refractory CLL/SLL, a phase 3 trial suggests.
Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.
Researchers sought to determine whether emicizumab would be effective in treating infants with severe hemophilia A without factor VIII inhibitors.
Blinatumomab-based consolidation is a new standard of care for ALL patients with MRD negativity after induction and intensification, researchers say.
Results from the MEDALIST, ASCERTAIN, STIMULUS-MDS1, and SINTRA-REV trials may help inform the treatment of MDS.
Preclinical research suggests that a monoclonal antibody may be effective for treating CALR-mutant myeloproliferative neoplasms.
Salvage chemotherapy before allogeneic transplant does not improve outcomes in relapsed/refractory acute myeloid leukemia, a phase 3 study suggests.
Progression is “uncommon” in patients with relapsed/refractory large B-cell lymphoma who are in complete remission at the end of glofitamab treatment.
Combination ponatinib and blinatumomab produced durable responses in patients with newly diagnosed Ph+ acute lymphoblastic leukemia in a phase 2 trial.
Rapcabtagene autoleucel may elicit durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
Researchers sought to determine whether combining pozelimab and cemdisiran would be an effective treatment for patients with PNH.